Sun Pharma Signs Global Exclusive Deal with Philogen for Commercializing FIBROMUN
Under the terms of the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun.
Philogen | 01/10/2024 | By Aishwarya
EMA Approves Marketing Authorization Application of Nidlegy
Philogen and Sun Pharmaceutical Industries Ltd. have announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy.
Philogen | 05/07/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy